We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $138.89, moving -1.48% from the previous trading session. This change lagged the S&P 500's 1.76% gain on the day. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 3.03%.
Prior to today's trading, shares of the drugmaker had gained 0.01% over the past month. This has outpaced the Medical sector's loss of 4.26% and the S&P 500's loss of 5.94% in that time.
Novo Nordisk will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.04, up 10.64% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.7 billion, up 5.71% from the year-ago period.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $4.43 per share and revenue of $29.81 billion. These results would represent year-over-year changes of +28.03% and +19.11%, respectively.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.42% higher. Novo Nordisk currently has a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Novo Nordisk currently has a Forward P/E ratio of 31.84. Its industry sports an average Forward P/E of 13.88, so we one might conclude that Novo Nordisk is trading at a premium comparatively.
We can also see that NVO currently has a PEG ratio of 1.49. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $138.89, moving -1.48% from the previous trading session. This change lagged the S&P 500's 1.76% gain on the day. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 3.03%.
Prior to today's trading, shares of the drugmaker had gained 0.01% over the past month. This has outpaced the Medical sector's loss of 4.26% and the S&P 500's loss of 5.94% in that time.
Novo Nordisk will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.04, up 10.64% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.7 billion, up 5.71% from the year-ago period.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $4.43 per share and revenue of $29.81 billion. These results would represent year-over-year changes of +28.03% and +19.11%, respectively.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.42% higher. Novo Nordisk currently has a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Novo Nordisk currently has a Forward P/E ratio of 31.84. Its industry sports an average Forward P/E of 13.88, so we one might conclude that Novo Nordisk is trading at a premium comparatively.
We can also see that NVO currently has a PEG ratio of 1.49. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.